Achyut Healthcare Ltd

ACHYUTPharmaceuticals
5.27+0.00 (+0.00%)
As on 29 Jan 2026, 10:34 amMarket Closed

Fundamental Score

...

Achyut Healthcare Ltd Share Price Live NSE/BSE

No data
High
0.00
Low
0.00
Volume
0
Change
+0.00%

Profitability Metrics

Poor

Return on Equity

1.77%
Poor

Return on Capital Employed

2.26%
Poor

Operating Profit Margin (5Y)

-2.90%
Poor

Dividend Yield

0.00%

Valuation Metrics

Poor

Price to Earnings

307.33x

Market Capitalization

132.15 (Cr)

Industry P/E

31.77x

Growth Metrics

Poor

YoY Quarterly Profit Growth

-34.29%
Excellent

YoY Quarterly Sales Growth

164.79%
Excellent

Sales Growth (5Y)

56.01%
Poor

EPS Growth (5Y)

6.98%
Excellent

Profit Growth (5Y)

122.88%

Financial Health

Excellent

Debt to Equity

0.00x

Interest Coverage

N/A
Poor

Free Cash Flow (5Y)

-32.02 (Cr)

Ownership Structure

Average

Promoter Holding

47.07%
Average

FII Holding

5.26%
Poor

DII Holding

0.00%
Excellent

Pledged Percentage

0.00%
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.
47.07%
Promoter Holding
132.15 (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of ACHYUT across key market metrics for learning purposes.

Positive Indicators

5 factors identified

Strong Revenue Growth (164.79%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.

Consistent Growth Track Record (56.01% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.

Strong Profit Growth Track Record (122.88% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.

Debt-Free Balance Sheet (D/E: 0.00)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral, reducing forced-selling risk.

Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.

Risk Factors

12 factors identified

Below-Average Return on Equity (1.77%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (2.26%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.

Margin Pressure Concerns (-2.90%)

Observation: Operating margins are below industry standards.

Analysis: OPM <5% may indicate pricing pressures or cost management challenges. Monitor for operational improvements.

Premium Valuation Risk (P/E: 307.33x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.

Profit Decline Concern (-34.29%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.

Negative Free Cash Flow (₹-32.02 Cr over 5Y)

Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.

Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.

Limited Institutional Interest (FII+DII: 5.26%)

Observation: Low institutional participation may affect liquidity and visibility.

Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.

Very Low ROE

Observation: Poor capital utilization and shareholder returns.

Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.

High P/E Ratio

Observation: Stock may be overvalued relative to earnings.

Analysis: P/E above 30 requires strong growth execution to justify current valuations.

Very High P/E Ratio

Observation: Significant overvaluation risk present.

Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.

Small Market Cap

Observation: Higher investment risk due to limited size.

Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.

Financial Statements

Comprehensive financial data for Achyut Healthcare Ltd

About ACHYUT

Business Overview

Achyut Healthcare Limited engages in manufacturing and sale of pharmaceutical formulations in India. The company offers its products in the form of tablets, capsules, oral liquids, and injectables. It also deals in APIs, pharmaceutical products, and medical devices. The company exports its products. The company was incorporated in 1996 and is based in Ahmedabad, India.

Company Details

Symbol:ACHYUT
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Jigen Jagdishbhai Modi
MD, CFO & Executive Director
Mr. Kaushalkumar Shrikrishnabhai Dave
Company Secretary & Compliance Officer
Ms. Amisha Jigen Modi
Executive Director

ACHYUT Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)1.77%
Return on Capital Employed2.26%
Operating Profit Margin (5Y)-2.90%
Debt to Equity Ratio0.00
Interest Coverage RatioN/A

Growth & Valuation

Sales Growth (5Y)56.01%
Profit Growth (5Y)122.88%
EPS Growth (5Y)6.98%
YoY Quarterly Profit Growth-34.29%
YoY Quarterly Sales Growth164.79%

Frequently Asked Questions

What is the current price of Achyut Healthcare Ltd (ACHYUT)?

As of 29 Jan 2026, 10:34 am IST, Achyut Healthcare Ltd (ACHYUT) is currently trading at ₹5.27. The stock has a market capitalization of ₹132.15 (Cr).

Is ACHYUT share price Overvalued or Undervalued?

ACHYUT is currently trading at a P/E ratio of 307.33x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.

What factors affect the Achyut Healthcare Ltd share price?

Key factors influencing ACHYUT's price include its quarterly earnings growth (Sales Growth: 164.79%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is Achyut Healthcare Ltd a good stock for long-term investment?

Achyut Healthcare Ltd shows a 5-year Profit Growth of 122.88% and an ROE of 1.77%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing.

How does Achyut Healthcare Ltd compare with its industry peers?

Achyut Healthcare Ltd competes with major peers in the Pharmaceuticals. Investors should compare ACHYUT's P/E of 307.33x and ROE of 1.77% against the industry averages to determine its competitive standing.

What is the P/E ratio of ACHYUT and what does it mean?

ACHYUT has a P/E ratio of 307.33x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹307 for every ₹1 of annual earnings.

How is ACHYUT performing according to Bull Run's analysis?

ACHYUT has a Bull Run fundamental score of 41.1/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.

What sector and industry does ACHYUT belong to?

ACHYUT operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Achyut Healthcare Ltd.

What is Return on Equity (ROE) and why is it important for ACHYUT?

ACHYUT has an ROE of 1.77%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Achyut Healthcare Ltd generates profits from shareholders' equity.

How is ACHYUT's debt-to-equity ratio and what does it indicate?

ACHYUT has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.

What is ACHYUT's dividend yield and is it a good dividend stock?

ACHYUT offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.

How has ACHYUT grown over the past 5 years?

ACHYUT has achieved 5-year growth rates of: Sales Growth 56.01%, Profit Growth 122.88%, and EPS Growth 6.98%.

What is the promoter holding in ACHYUT and why does it matter?

Promoters hold 47.07% of ACHYUT shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.

What is ACHYUT's market capitalization category?

ACHYUT has a market capitalization of ₹132 crores, placing it in the Small-cap category.

How volatile is ACHYUT stock?

ACHYUT has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is the 52-week high and low for ACHYUT?

ACHYUT has a 52-week high of ₹N/A and low of ₹N/A.

What is ACHYUT's operating profit margin trend?

ACHYUT has a 5-year average Operating Profit Margin (OPM) of -2.90%, indicating the company's operational efficiency.

How is ACHYUT's quarterly performance?

Recent quarterly performance shows YoY Sales Growth of 164.79% and YoY Profit Growth of -34.29%.

What is the institutional holding pattern in ACHYUT?

ACHYUT has FII holding of 5.26% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.